Fragile X study offers hope of new autism treatment
News Nov 27, 2014
Drug reverses behavioural symptoms in mice with a version of autism
People affected by a common inherited form of autism could be helped by a drug that is being tested as a treatment for cancer, according to researchers from the University of Edinburgh and McGill University.
Fragile X Syndrome is the most common genetic cause of autism spectrum disorders. It affects around 1 in 4,000 boys and 1 in 6,000 girls. Currently, there is no cure.
The scientists, who have identified a chemical pathway that goes awry in the brains of Fragile X patients, say a cancer drug candidate could reverse their behavioural symptoms. The researchers have found that a naturally occurring anti-fungal called cercosporamide can block the pathway and improve sociability in mice with the condition.
The team identified a key molecule – eIF4E – that drives excess protein production in the brains of Fragile X patients. This can cause behavioural symptoms that include learning difficulties. It can also lead to more serious intellectual disabilities, delays in speech and language development and problems with social interactions.
“We found that eIF4E regulates the production of an enzyme called MMP-9, which breaks down and re-orders the connections between brain cells called synapses,” says Nahum Sonenberg, McGill professor in the Faculty of Medicine and the Goodman Cancer Research Centre and co-author of the study, “Excess MMP-9 disrupts communication between brain cells, leading to changes in behaviour.”
The team found that treatment with cercosporamide blocks the activity of eIF4E, and therefore reduces the amounts of MMP-9, and reverses the behavioural symptoms in mice with a version of Fragile X Syndrome. The new findings suggest that it could have a use as a treatment for patients with Fragile X Syndrome. The study is published in the journal Cell Reports.
Findings open door to targeted treatments
McGill post-doctoral student and a co-first author of the study Arkady Khoutorsky said that “the enzyme MMP-9 has been implicated before in Fragile X Syndrome. What’s new in our research is the demonstration that the symptoms of the disease can be controlled by manipulating eIF4E activity with available drug candidates.”
“Our findings open the door to targeted treatments for Fragile X Syndrome,” says Christos Gkogkas, of the University of Edinburgh’s Patrick Wild Centre for Research into Autism, Fragile X Syndrome and Intellectual Disabilities. “By designing treatments that block just this pathway, it is hoped that we can limit the potential side-effects and develop therapies that are more efficient than general treatment approaches.”
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Christos G. Gkogkas, Arkady Khoutorsky, Ruifeng Cao, Seyed Mehdi Jafarnejad, Masha Prager-Khoutorsky, Nikolaos Giannakas, Archontia Kaminari, Apostolia Fragkouli, Karim Nader, Theodore J. Price, Bruce W. Konicek, Jeremy R. Graff, Athina K. Tzinia, Jean-Claude Lacaille, Nahum Sonenberg. Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes. Cell Reports, Published Online November 26 2014. doi: 10.1016/j.celrep.2014.10.064
Neurons in the human brain receive electrical signals from thousands of other cells, and long neural extensions called dendrites play a critical role in incorporating all of that information. Using hard-to-obtain samples of human brain tissue, MIT neuroscientists have now discovered that human dendrites have different electrical properties from those of other species.